Author | Scheffold, Annika | dc.contributor.author |
Author | Stilgenbauer, Stephan | dc.contributor.author |
Date of accession | 2020-03-19T09:29:57Z | dc.date.accessioned |
Available in OPARU since | 2020-03-19T09:29:57Z | dc.date.available |
Date of first publication | 2020 | dc.date.issued |
Language | en | dc.language.iso |
Publisher | Universität Ulm | dc.publisher |
Keyword | Chronic lymphocytic leukemia | dc.subject |
Keyword | BCR signaling | dc.subject |
Keyword | BTK inhibitor | dc.subject |
Keyword | Venetoclax | dc.subject |
Keyword | BCL2 inhibitors | dc.subject |
Keyword | PREVIOUSLY UNTREATED PATIENTS | dc.subject |
Keyword | OPEN-LABEL | dc.subject |
Keyword | PLUS FLUDARABINE | dc.subject |
Keyword | OLIGOMERIZES BAK | dc.subject |
Keyword | RITUXIMAB | dc.subject |
Keyword | IBRUTINIB | dc.subject |
Keyword | CYCLOPHOSPHAMIDE | dc.subject |
Keyword | INHIBITOR | dc.subject |
Keyword | GENE | dc.subject |
Dewey Decimal Group | DDC 610 / Medicine & health | dc.subject.ddc |
Title | Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm | dc.title |
Resource type | Wissenschaftlicher Artikel | dc.type |
Institution | UKU. Klinik für Innere Medizin III | uulm.affiliationSpecific |
DCMI Type | Text | uulm.typeDCMI |
Category | Publikationsnachweise | uulm.category |
DOI (external) | 10.1007/s11912-020-0881-4 | dc.identifier.doiExternal |
Source - Title of source | Current Oncology Reports | source.title |
Source - Place of publication | Springer | source.publisher |
Source - Volume | 22 | source.volume |
Source - Issue | 2 | source.issue |
Source - Year | 2020 | source.year |
Source - Article number | 16 | source.articleNumber |
Source - ISSN | 1523-3790 | source.identifier.issn |
Source - eISSN | 1534-6269 | source.identifier.eissn |
Open Access | Other Gold, Green Published | uulm.OA |
Suitable community | Universitätsklinikum Ulm | uulm.community |
WoS | 000514287600002 | uulm.identifier.wos |
University Bibliography | ja | uulm.unibibliographie |